

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-19871
(Commission
File Number)

94-3078125
(IRS Employer
Identification No.)

175 Derby St., Bld. 27
Hingham, MA 02043
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, \$0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On June 16, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it has entered into a vendor agreement with Lovell Government Services, which creates an opportunity to sell the Company’s LIBERTY[®] Endovascular Robotic System at more than 2,000 U.S. government facilities.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.*(d) Exhibits*

Exhibit Number	Description
99.1	Press Release
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: /s/ Harel Gadot

Name: Harel Gadot

Title: Chief Executive Officer, President and Chairman

Date: June 16, 2026



Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations

The agreement with Lovell Government Services creates opportunities to sell the LIBERTY® System at more than 2,000 government facilities, including those administered by the U.S. Department of Veterans Affairs, the Department of Defense, and the Indian Health Service.

HINGHAM, Mass., June 16, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement with Lovell® Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration (VHA), a division of the U.S. Department of Veteran Affairs, the Military Health System (MHS), which is run by the U.S. Department of Defense, and the U.S. Indian Health Service (IHS). Lovell Government Services will become the Company’s Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems.

Lovell Government Services has been a SDVOSB vendor since 2013 with a track record of introducing suppliers to the government market. Lovell is a four-time Inc. 5000 honoree. Microbot Medical’s LIBERTY System will be added to Lovell’s Federal Supply Schedule (FSS) contract, with activation expected during the third quarter of 2026. The LIBERTY System will also be accessible through additional federal procurement platforms, including GSA Advantage, the Defense Logistics Agency’s Electronic Catalog (ECAT), and the Department of Defense’s Distribution and Pricing Agreement (DAPA). Listing products with Lovell is expected to streamline the sales process while helping government agencies meet their SDVOSB procurement goals. Lovell serves thousands of government care sites nationwide, including 170 medical centers and numerous outpatient clinics, averaging over 200 peripheral endovascular cases annually, per site.

“We are proud to partner with Microbot Medical to help expand access to innovative healthcare technologies for our nation’s veterans, active-duty service members, and Native American communities,” said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services. “The LIBERTY® Endovascular Robotic System represents a significant advancement in minimally invasive vascular care, and we look forward to supporting its availability across federal healthcare systems. Our mission is to connect government providers with best-in-class solutions that improve patient outcomes while simplifying the procurement process, and this partnership reflects that commitment.”

“As someone who has represented the U.S. in two Olympics, it is an honor to join with Lovell to ensure those who have served in the military along with their physicians have access to advanced medical technologies that address their needs,” commented Christina Bailey, Vice President, U.S. Sales. “Building on our continued commercial momentum, we believe this partnership will expand awareness and adoption of our technology across Lovell’s extensive network. Contracted access is a key component of our commercial strategy, providing customers with a streamlined procurement pathway and confidence in product availability. As interest in our technology continues to grow, we believe now is the right time to start this relationship and its potential for broader adoption.”

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY[®] Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on [LinkedIn](#) and [X](#).

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as "contemplates," "continues," "could," "forecasts," "intends," "may," "might," "possible," "potential," "predicts," "projects," "should," "would," "will," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY[®] Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical[®] can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical[®] disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:

IR@microbotmedical.com

Media@microbotmedical.com
